Omeros Corp - Company Profile
Powered by 
All the data and insights you need on Omeros Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Omeros Corp Strategy Report
- Understand Omeros Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
The following section provides information on Omeros Corp’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into Omeros Corp's management and employees, unlock the full data with our company analytics monitoring tool.
Executives
Gregory A. Demopulos, M.D.
Chairman; President; Chief Executive Officer Executive BoardDr. Gregory A. Demopulos has been the Chairman, Chief Executive Officer and President of the company since 2013. Prior to this, he served as the Chief Financial Officer and Treasurer from January 2009 to October 2013 in an interim capacity. Dr. Demopulos also served as Chief Medical Officer from June 1994 to March 2010. He has also served on the board of Smead Funds Trust.
Michael A. Jacobsen
Chief Accounting Officer; Vice President - Finance; Treasurer Senior ManagementMr. Michael A. Jacobsen has been the Vice President of Finance, Chief Accounting Officer and Treasurer since October 2013. Prior to this, he served as Vice President of Finance of Sarepta Therapeutics, Inc. Mr. Jacobsen also served as the Vice President and Chief Accounting Officer at ZymoGenetics Inc. He also held various roles at ICOS Corporation as a Senior Director of Finance and Corporate Controller, Vice President of Finance in the software, computer hardware and internet retailing industries.
Andreas Grauer, M.D.
Chief Medical Officer Senior ManagementMr. Andreas Grauer has been the Chief Medical Officer of the company since October 2023. Prior to this, he served as the Chief Medical Officer at Corcept Therapeutics. Previously, he served as the Global Executive Medical Director for bone and for new technology development at Proctor and Gamble Pharmaceuticals.
George A. Gaitanaris, M.D., Ph.D.
Vice President - Science; Chief Scientific Officer Senior ManagementDr. George A. Gaitanaris has been the Chief Scientific Officer and Vice President of Science since 2012. Prior to this, he was the Chief Scientific Officer of Nura Inc. Dr. Gaitanaris also served as President and Chief Scientific Officer of Primal Inc. Prior to that, he served as Staff Scientist at the National Cancer Institute.
Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs & Quality Systems; Chief Regulatory Officer Senior ManagementDr. Catherine A. Melfi has been the Chief Regulatory Officer and Vice President of Regulatory Affairs & Quality Systems of the company since April 2016. Prior to this, she has been the Vice President of Regulatory Affairs and Quality Systems since October 2012. She has also worked at Eli Lilly and Company and held various leadership roles in the company.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer